Genfleet Therapeutics (Shanghai) Inc. clinical trials
The registry lists 23 studies whose lead sponsor is Genfleet Therapeutics (Shanghai) Inc. or one of 2 companies grouped under it. 14 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 6, 2026.
Our grouping of 3 registry names, not the registry’s. See them and correct one ↓
- 23studies on the registry
- 14open to participants now
- 3phase 3 studies under way
- 6reach primary completion within a year
Get an email when these change. Save the Genfleet Therapeutics (Shanghai) Inc. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Pipeline: 3 programmes
Each counted once: 3 with a study Genfleet Therapeutics (Shanghai) Inc. leads registered in the last two years.
The 1 phase-3 programme — sign in to see them, free: with every programme, filter by condition or phase and sort by first study or primary completion.
The 3 programmes — sign in to see the list, free: with every programme, filter by condition or phase and sort by first study or primary completion.
Not counted: 4 approved drugs Genfleet Therapeutics (Shanghai) Inc. gives alongside its own in its studies — bevacizumab (with GFH276); carboplatin (with GFH276); cisplatin (with GFH276); pemetrexed (with GFH276). Our rule: a drug many companies test, in every study Genfleet Therapeutics (Shanghai) Inc. led of it in the last two years beside a drug of its own.
Companies developing a programme in the same conditions as Genfleet Therapeutics (Shanghai) Inc.’s (4 conditions its studies of the last two years are mainly about), ranked by how directly they meet: a programme tested against the other’s drug, read from the study’s arms; then the conditions where both are in phase 3; then the conditions shared. Size plays no part.
- Otsuka Holdings Co., Ltd.1 condition shared, 1 with both in phase 3: Carcinoma, Non-Small-Cell Lung
- Genfleet Therapeutics (Shanghai) Inc.’s KRAS G12D Inhibitor VS-7375 vs trifluridine tipiracil drug combination (most trials: Otsuka Holdings Co., Ltd.) (Colorectal Neoplasms, NCT07913360)
- Qilu Pharmaceutical Co., Ltd.4 conditions shared, 3 with both in phase 3: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Pancreatic Neoplasms +1
- Jiangsu HengRui Medicine Co., Ltd.3 conditions shared, 3 with both in phase 3: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Pancreatic Neoplasms
- Bristol-Myers Squibb3 conditions shared, 3 with both in phase 3: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Pancreatic Neoplasms
- Sino Biopharmaceutical Limited3 conditions shared, 2 with both in phase 3: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Pancreatic Neoplasms
| Company | Conditions shared | Their phase 3 there | Where they meet, by arms |
|---|---|---|---|
| Otsuka Holdings Co., Ltd.1 programme in shared conditions | 1 · 1 with both in phase 3Carcinoma, Non-Small-Cell Lung | zipalertinib |
|
| Qilu Pharmaceutical Co., Ltd.6 programmes in shared conditions | 4 · 3 with both in phase 3Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Pancreatic Neoplasms +1 | QL2107, QL1203, Iparomlimab/Tuvonralimab +1 | no study of one against the other’s drug |
| Jiangsu HengRui Medicine Co., Ltd.15 programmes in shared conditions | 3 · 3 with both in phase 3Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Pancreatic Neoplasms | ruzaltatug rezetecan, adebrelimab, aumolertinib +7 | no study of one against the other’s drug |
| Bristol-Myers Squibb8 programmes in shared conditions | 3 · 3 with both in phase 3Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Pancreatic Neoplasms | Nivolumab, izalontamab brengitecan, pumitamig +3 | no study of one against the other’s drug |
| Sino Biopharmaceutical Limited9 programmes in shared conditions | 3 · 2 with both in phase 3Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Pancreatic Neoplasms | FHND-9041, Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102, trifluridine tipiracil drug combination | no study of one against the other’s drug |
196 more companies — sign in to see them all, free.
Also leading studies of the same drugs, not counted as competitors (a partner, a licensee, a biosimilar maker, or a combination study): Verastem, Inc. (KRAS G12D Inhibitor VS-7375).
“Registry” is the highest phase of Genfleet Therapeutics (Shanghai) Inc.’s own registered studies; Genfleet Therapeutics (Shanghai) Inc.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.
What it is testing
The drugs Genfleet Therapeutics (Shanghai) Inc.’s studies test, most open studies first — 10 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
Coming up
6 of Genfleet Therapeutics (Shanghai) Inc.’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- JJan ’27’27
- FFeb
- MMar
- 1AApr
- MMay
- 1JJun
- 1JJul
- AAug
- 1SSep
- OOct
- 1NNov
All 6
- Dec 2026A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCLtambiciclib · NCT06375733
- Apr 2027GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung CancerKRAS G12D Inhibitor VS-7375 · NCT07554859
- Jun 2027Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic CancerKRAS G12D Inhibitor VS-7375 · Phase 3 · NCT07262567
- Jul 2027A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D MutationKRAS G12D Inhibitor VS-7375 · NCT07259590
- Sep 2027A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid TumorsGFH276 · NCT07198321
Show 1 moreShow fewer
Add all 6 to your calendar (.ics) → With an account.
What changed recently
From the registry's own updates since Oct 15, 2026.
Newly registered2
- A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerNov 4, 2026NCT07915921
- GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal CancerNov 3, 2026NCT07913360
All 23 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 726
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Genfleet Therapeutics (Shanghai) Inc..
- Genfleet Therapeutics (Shanghai) Inc.18 studiesSame company
Something wrong?
- Zhejiang Genfleet Therapeutics Co., Ltd.4 studies →Subsidiary
Something wrong?
- GenFleet Therapeutics (Australia) Pty Ltd.1 study →Regional office
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 23 of 23.
- A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerNot yet recruitingNCT07915921Phase 1/2
- GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal CancerNot yet recruitingNCT07913360Phase 3
- A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS MutationRecruitingNCT07678593Phase 1/2
- A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D MutationRecruitingNCT07784374Phase 2
- This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.Not yet recruitingNCT07846358Phase 1/2
- Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic CancerRecruitingNCT07262567Phase 3
- A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D MutationRecruitingNCT07668752Phase 3
- GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung CancerNot yet recruitingNCT07554859Phase 2
- A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D MutationRecruitingNCT07259590Phase 1/2
- A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D MutationsRecruitingNCT06500676Phase 1/2
- A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid TumorsNot yet recruitingNCT07198321Phase 1/2
- A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCLRecruitingNCT06375733Phase 1/2
- A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or CachexiaRecruitingNCT06898255Phase 1
- A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)RecruitingNCT05934513Phase 1/2
- A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic CancerWithdrawnNCT07026916Phase 2
- A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLCCompletedNCT05386888Phase 2
- A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C MutationCompletedNCT05756153Phase 1/2
- A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid TumorsCompletedNCT04914286Phase 1/2
- A Study of GFH018 in Patients With Advanced Solid TumorsCompletedNCT05051241Phase 1
Sponsor listed in the registry: Zhejiang Genfleet Therapeutics Co., Ltd.
- A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)WithdrawnNCT05618691Phase 2
Sponsor listed in the registry: Zhejiang Genfleet Therapeutics Co., Ltd.
- A Phase I Study of GFH312 in Healthy Chinese SubjectsCompletedNCT05991362Phase 1
Sponsor listed in the registry: Zhejiang Genfleet Therapeutics Co., Ltd.
- A Study of GFH312 in Healthy SubjectsCompletedNCT04676711Phase 1
Sponsor listed in the registry: GenFleet Therapeutics (Australia) Pty Ltd.
- A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid TumorsWithdrawnNCT05165849Phase 1/2
Sponsor listed in the registry: Zhejiang Genfleet Therapeutics Co., Ltd.